Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress Read more about Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
Travere Therapeutics to Present at Upcoming Investor Conferences Read more about Travere Therapeutics to Present at Upcoming Investor Conferences
Travere Therapeutics Reports First Quarter 2024 Financial Results Read more about Travere Therapeutics Reports First Quarter 2024 Financial Results
Travere Therapeutics to Report First Quarter 2024 Financial Results Read more about Travere Therapeutics to Report First Quarter 2024 Financial Results
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy Read more about Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International Read more about Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association Read more about Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)